Increased eyelid pigmentation associated with use of latanoprost.
OBJECTIVE
To report increased eyelid pigmentation as an adverse side effect associated with topical latanoprost.


METHODS
Case report. A 62-year-old Korean woman with normal-tension glaucoma developed bilateral increased eyelid skin pigmentation 4 months after beginning treatment with latanoprost in both eyes. Clinical examinations were performed, and external photographs were taken.


RESULTS
Latanoprost was discontinued. Periodic examinations revealed that the eyelid skin pigmentation gradually diminished 1 month after the cessation of the drug, and decrease in pigmentation continued over 4 months of follow-up.


CONCLUSIONS
An increase in eyelid skin pigmentation is a possible complication of topical latanoprost therapy, and the cessation of the drug can result in loss of induced pigmentation in humans.
Kook
M S
MS
Department of Ophthalmology, Ulsan University School of Medicine, Asan Medical Center, Seoul, South Korea.
Lee
K
K
D000959:Antihypertensive Agents / Q000009:adverse effects*; D005141:Eyelid Diseases / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000139:chemically induced* / Q000473:pathology; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects*; D012880:Skin Pigmentation
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost